HALEON PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 331.1 GBX | -0.12% |
|
-0.06% | +2.94% |
| May. 21 | Bernstein becomes more optimistic for consumer goods - Henkel upgraded | DP |
| May. 17 | UK's FTSE 100 Closes Lower Amid Inflation Focus | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 11.45B 14.58B | Sales 2025 * | 11.93B 15.19B | Capitalization | 30.27B 38.54B |
|---|---|---|---|---|---|
| Net income 2024 * | 1.46B 1.86B | Net income 2025 * | 1.69B 2.15B | EV / Sales 2024 * | 3.33 x |
| Net Debt 2024 * | 7.81B 9.95B | Net Debt 2025 * | 7.07B 9B | EV / Sales 2025 * | 3.13 x |
| P/E ratio 2024 * |
20.7
x | P/E ratio 2025 * |
18
x | Employees | 25,408 |
| Yield 2024 * |
1.86% | Yield 2025 * |
2.15% | Free-Float | 81.7% |
More Fundamentals
* Assessed data
More news
Latest transcript on Haleon plc
More press releases
| 1 day | -0.78% | ||
| 1 week | -0.99% | ||
| Current month | -3.38% | ||
| 1 month | -0.87% | ||
| 3 months | +0.47% | ||
| 6 months | -0.08% | ||
| Current year | +1.98% |
1 week
325.70
371.20
1 month
325.40371.20
Current year
308.37371.20
1 year
306.80371.20
3 years
241.17371.20
5 years
241.17371.20
10 years
241.17371.20
| Managers | Title | Age | Since |
|---|---|---|---|
Brian McNamara
CEO | Chief Executive Officer | 57 | 21-07-21 |
Tobias Hestler
DFI | Director of Finance/CFO | 52 | 21-11-30 |
Franck Riot
CTO | Chief Tech/Sci/R&D Officer | - | 21-12-15 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Bryan Supran
BRD | Director/Board Member | - | 22-07-17 |
Dame Cox
BRD | Director/Board Member | 64 | 22-07-17 |
Tracy Clarke
BRD | Director/Board Member | 57 | 22-07-17 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.35% | 142 M€ | +13.04% | - | |
| 0.99% | 11 M€ | +0.83% | - | |
| 0.94% | 5 M€ | +15.67% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-22 | 331.1 | -0.12% | 12 518 361 |
| 24-05-21 | 331.5 | -0.15% | 71,444,470 |
| 24-05-20 | 332 | +0.91% | 24,594,140 |
| 24-05-17 | 329 | -1.02% | 39,617,990 |
| 24-05-16 | 332.4 | +0.33% | 11,804,850 |
Delayed Quote London S.E., May 22, 2024 at 10:40 am EDT
More quotes
Haleon plc specializes in the research, manufacture and marketing of drugs and consumer pharmaceutical products. Net sales break down by family of products as follows:
- oral health products (27.7%; no. 1 worldwide): Sensodyne, Parodontax, Polident, Biotene, Aquafresh brands, etc.;
- Pain relief medicines (23.5%; no. 1 worldwide): Panadol, Advil, Voltaren, Excedrin brands, etc.;
- medicines for digestive health (18.9%; no. 1 worldwide): TUMS, Nicorette, ENO, Chap Stick, Fenistil, Nexium brands, etc.;
- respiratory medicines (15.4%; no. 1 worldwide): Theraflu, Otrivin, Flonase, Contac brands, etc.;
- vitamins, minerals and food supplements (14.5%; no. 1 worldwide): Centrum, Emergen-C, Caltrate brands, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa/Latin America (40.2%), North America (37.1%), and Asia/Pacific (22.7%).
Sector
Pharmaceuticals
Calendar
2024-08-01
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
3.315
GBP
Average target price
3.62
GBP
Spread / Average Target
+9.20%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +1.98% | 38.49B | |
| +37.48% | 723B | |
| +31.83% | 598B | |
| -2.48% | 364B | |
| +20.28% | 331B | |
| +3.32% | 288B | |
| +16.13% | 244B | |
| +9.78% | 210B | |
| -5.19% | 208B | |
| +8.63% | 169B |
- Stock Market
- Equities
- HLN Stock
